Last edition
News about "ophthalmology biosimilar Byooviz"
Samsung Bioepis Relaunches Byooviz in US Through Commercial Partnership with Harrow
Samsung Bioepis has relaunched its ophthalmology biosimilar Byooviz in the US through its partnership with Harrow, expanding access to a lower-cost treatment option for patients with retinal diseases, including wet age-related macular degeneration.
Ophthalmology Biosimilar Byooviz | 03/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members